VERACYTE INC (VCYT)
US92337F1075 - Common Stock
Overall VCYT gets a fundamental rating of 5 out of 10. We evaluated VCYT against 565 industry peers in the Biotechnology industry. VCYT is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. VCYT has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
VCYT had negative earnings in the past year.
VCYT had a positive operating cash flow in the past year.
In the past 5 years VCYT always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: VCYT reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of VCYT (-0.73%) is better than 92.04% of its industry peers.
VCYT has a Return On Equity of -0.79%. This is amongst the best in the industry. VCYT outperforms 93.27% of its industry peers.
VCYT's Return On Invested Capital of 0.60% is amongst the best of the industry. VCYT outperforms 93.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.73% | ||
| ROE | -0.79% | ||
| ROIC | 0.6% |
ROA(3y)-5.4%
ROA(5y)-5.68%
ROE(3y)-5.81%
ROE(5y)-6.19%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Operating Margin of VCYT (2.14%) is better than 93.63% of its industry peers.
With an excellent Gross Margin value of 68.45%, VCYT belongs to the best of the industry, outperforming 82.12% of the companies in the same industry.
In the last couple of years the Gross Margin of VCYT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.14% | ||
| PM (TTM) | N/A | ||
| GM | 68.45% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.04%
GM growth 5Y1.43%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so VCYT is destroying value.
VCYT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for VCYT has been increased compared to 5 years ago.
Compared to 1 year ago, VCYT has an improved debt to assets ratio.
2.2 Solvency
VCYT has an Altman-Z score of 19.34. This indicates that VCYT is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of VCYT (19.34) is better than 92.04% of its industry peers.
VCYT has a debt to FCF ratio of 0.00. This is a very positive value and a sign of high solvency as it would only need 0.00 years to pay back of all of its debts.
The Debt to FCF ratio of VCYT (0.00) is better than 97.70% of its industry peers.
VCYT has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
VCYT's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. VCYT outperforms 50.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 19.34 |
ROIC/WACC0.05
WACC10.91%
2.3 Liquidity
VCYT has a Current Ratio of 5.08. This indicates that VCYT is financially healthy and has no problem in meeting its short term obligations.
VCYT has a Current ratio (5.08) which is in line with its industry peers.
VCYT has a Quick Ratio of 4.79. This indicates that VCYT is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of VCYT (4.79) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.08 | ||
| Quick Ratio | 4.79 |
3. Growth
3.1 Past
VCYT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 78.26%, which is quite impressive.
Looking at the last year, VCYT shows a very strong growth in Revenue. The Revenue has grown by 23.95%.
VCYT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 31.45% yearly.
EPS 1Y (TTM)78.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%146.34%
Revenue 1Y (TTM)23.95%
Revenue growth 3Y45.38%
Revenue growth 5Y31.45%
Sales Q2Q%28.58%
3.2 Future
Based on estimates for the next years, VCYT will show a very strong growth in Earnings Per Share. The EPS will grow by 29.09% on average per year.
The Revenue is expected to grow by 12.45% on average over the next years. This is quite good.
EPS Next Y133.81%
EPS Next 2Y58.82%
EPS Next 3Y41.29%
EPS Next 5Y29.09%
Revenue Next Year24.95%
Revenue Next 2Y17.3%
Revenue Next 3Y15.04%
Revenue Next 5Y12.45%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VCYT. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 76.00, the valuation of VCYT can be described as expensive.
VCYT's Price/Forward Earnings ratio is rather cheap when compared to the industry. VCYT is cheaper than 92.04% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.73. VCYT is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 76 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of VCYT indicates a rather cheap valuation: VCYT is cheaper than 93.45% of the companies listed in the same industry.
VCYT's Price/Free Cash Flow ratio is rather cheap when compared to the industry. VCYT is cheaper than 93.98% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 56.11 | ||
| EV/EBITDA | 88.65 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as VCYT's earnings are expected to grow with 41.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.82%
EPS Next 3Y41.29%
5. Dividend
5.1 Amount
No dividends for VCYT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VERACYTE INC
NASDAQ:VCYT (12/20/2024, 8:00:01 PM)
After market: 40.89 0 (0%)40.89
+1.82 (+4.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.12%
Inst Owner Change-0.79%
Ins Owners0.64%
Ins Owner Change-2.75%
Market Cap3.17B
Analysts83.33
Price Target43.86 (7.26%)
Short Float %3.86%
Short Ratio3.84
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)550.71%
Min EPS beat(2)522.32%
Max EPS beat(2)579.09%
EPS beat(4)3
Avg EPS beat(4)219.85%
Min EPS beat(4)-309.68%
Max EPS beat(4)579.09%
EPS beat(8)6
Avg EPS beat(8)101.91%
EPS beat(12)10
Avg EPS beat(12)77.99%
EPS beat(16)12
Avg EPS beat(16)59.31%
Revenue beat(2)2
Avg Revenue beat(2)7.66%
Min Revenue beat(2)3.44%
Max Revenue beat(2)11.88%
Revenue beat(4)4
Avg Revenue beat(4)5.42%
Min Revenue beat(4)1.69%
Max Revenue beat(4)11.88%
Revenue beat(8)8
Avg Revenue beat(8)5.58%
Revenue beat(12)12
Avg Revenue beat(12)6.21%
Revenue beat(16)16
Avg Revenue beat(16)7%
PT rev (1m)15.52%
PT rev (3m)27.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)821.98%
EPS NY rev (1m)94.31%
EPS NY rev (3m)174.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)11.13%
Revenue NY rev (1m)0.42%
Revenue NY rev (3m)1.64%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 76 | ||
| P/S | 7.45 | ||
| P/FCF | 56.11 | ||
| P/OCF | 47.92 | ||
| P/B | 2.69 | ||
| P/tB | 10.39 | ||
| EV/EBITDA | 88.65 |
EPS(TTM)-0.15
EYN/A
EPS(NY)0.54
Fwd EY1.32%
FCF(TTM)0.73
FCFY1.78%
OCF(TTM)0.85
OCFY2.09%
SpS5.49
BVpS15.17
TBVpS3.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.73% | ||
| ROE | -0.79% | ||
| ROCE | 0.76% | ||
| ROIC | 0.6% | ||
| ROICexc | 0.77% | ||
| ROICexgc | 12.07% | ||
| OM | 2.14% | ||
| PM (TTM) | N/A | ||
| GM | 68.45% | ||
| FCFM | 13.28% |
ROA(3y)-5.4%
ROA(5y)-5.68%
ROE(3y)-5.81%
ROE(5y)-6.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.04%
GM growth 5Y1.43%
F-Score7
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 40.97% | ||
| Cap/Sales | 2.27% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 202.48% | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.08 | ||
| Quick Ratio | 4.79 | ||
| Altman-Z | 19.34 |
F-Score7
WACC10.91%
ROIC/WACC0.05
Cap/Depr(3y)32.36%
Cap/Depr(5y)39.97%
Cap/Sales(3y)2.7%
Cap/Sales(5y)2.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%146.34%
EPS Next Y133.81%
EPS Next 2Y58.82%
EPS Next 3Y41.29%
EPS Next 5Y29.09%
Revenue 1Y (TTM)23.95%
Revenue growth 3Y45.38%
Revenue growth 5Y31.45%
Sales Q2Q%28.58%
Revenue Next Year24.95%
Revenue Next 2Y17.3%
Revenue Next 3Y15.04%
Revenue Next 5Y12.45%
EBIT growth 1Y146.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year247.93%
EBIT Next 3Y63.42%
EBIT Next 5Y39.45%
FCF growth 1Y4512.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y959.68%
OCF growth 3YN/A
OCF growth 5YN/A